Objective:To investigate the effect of Olanzapine combined with Agomelatine on the positive and negative symptom scale(PANSS)score and depression levels in patients with schizophrenia and depressive symptoms.Method:A total of 82 schizophrenic patients with depressive symptoms admitted to the Third People's Hospital of Ganzhou from September 2021 to June 2022 were selected and divided into the control group(41 cases)and the study group(41 cases)by drawing lots.The control group was treated with Olanzapine combined with Duloxetine,while the study group was treated with Olanzapine combined with Agomelatine.The PANSS score,depression level,sleep quality,cognitive function and adverse reactions were compared between the two groups.Result:After 3 months of treatment,the PANSS,Hamilton depression scale(HAMD)and Pittsburgh sleep quality index(PSQI)scores in the study group were lower than those in the control group,while the Montreal cognitive scale(MoCA)score was higher than that in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Olanzapine combined with Argomepratine in the treatment of patients with schizophrenia and depressive symptoms can lower the PANSS score,lower the level of depression,improve sleep quality and cognitive function,with fewer adverse reactions and good safety.
关键词
精神分裂症/抑郁症状/奥氮平/阿戈美拉汀/阳性和阴性症状量表/抑郁水平
Key words
Schizophrenia/Depression symptoms/Olanzapine/Agomepratine/Positive and negative symptom scale/Depression level
维普
万方数据